GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Marketable Securities

ARDS (Aridis Pharmaceuticals) Marketable Securities : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Aridis Pharmaceuticals's Marketable Securities for the quarter that ended in Sep. 2023 was $0.00 Mil.


Aridis Pharmaceuticals Marketable Securities Historical Data

The historical data trend for Aridis Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Marketable Securities Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Marketable Securities
Get a 7-Day Free Trial - - - - -

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aridis Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Aridis Pharmaceuticals  (OTCPK:ARDS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Aridis Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Aridis Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Executives
Vu Truong director, 10 percent owner, officer: CEO, CSO, Director 5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer director, 10 percent owner 5941 OPTICAL CT., SAN JOSE CA 95138
Fibrosis Foundation Cystic 10 percent owner 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri officer: Chief Medical Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
John F Hamilton director 1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak officer: Chief Financial Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland officer: Chief Financial Officer C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer officer: Chief Medical Officer 5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo director
Shawn Lu director C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin director 5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025